Holen Sie sich die Stockscreener-App
21.31
6.29%
-1.43
Handel nachbörslich:
21.31
Schlusskurs vom Vortag:
$22.74
Offen:
$22.18
24-Stunden-Volumen:
1.28M
Relative Volume:
1.51
Marktkapitalisierung:
$1.37B
Einnahmen:
-
Nettoeinkommen (Verlust:
$-107.85M
KGV:
-9.6425
EPS:
-2.21
Netto-Cashflow:
$-106.82M
1W Leistung:
-19.98%
1M Leistung:
-25.49%
6M Leistung:
-47.82%
1J Leistung:
-43.04%
1-Tages-Spanne:
$20.27
$22.18
1-Wochen-Bereich:
$20.27
$25.00
52-Wochen-Spanne:
$20.27
$51.61
Vera Therapeutics Inc Stock (VERA) Company Profile
Firmenname
Vera Therapeutics Inc
Sektor
Branche
Telefon
650-770-0077
Adresse
2000 SIERRA POINT PARKWAY, SUITE 1200, BRISBANE
Vergleichen Sie VERA mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
VERA
Vera Therapeutics Inc
|
21.31 | 1.37B | 0 | -107.85M | -106.82M | -2.21 |
|
VRTX
Vertex Pharmaceuticals Inc
|
474.62 | 125.40B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
573.45 | 65.79B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
555.11 | 35.18B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
235.74 | 32.67B | 2.25B | -278.16M | -42.59M | -2.17 |
|
ONC
Beigene Ltd Adr
|
238.51 | 26.46B | 3.81B | -644.79M | -669.77M | -6.24 |
Vera Therapeutics Inc Stock (VERA) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-02-04 | Eingeleitet | Wolfe Research | Outperform |
| 2025-01-28 | Eingeleitet | Goldman | Buy |
| 2024-11-21 | Eingeleitet | Wells Fargo | Overweight |
| 2024-10-16 | Eingeleitet | Scotiabank | Sector Outperform |
| 2024-01-25 | Eingeleitet | Oppenheimer | Outperform |
| 2024-01-08 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2023-12-18 | Eingeleitet | Raymond James | Outperform |
| 2023-11-10 | Hochstufung | Jefferies | Hold → Buy |
| 2023-08-16 | Eingeleitet | Guggenheim | Buy |
| 2023-01-04 | Herabstufung | Jefferies | Buy → Hold |
| 2023-01-04 | Herabstufung | Wedbush | Outperform → Neutral |
| 2022-07-12 | Eingeleitet | JP Morgan | Overweight |
| 2022-05-02 | Eingeleitet | H.C. Wainwright | Buy |
| 2022-04-19 | Eingeleitet | Wedbush | Outperform |
Alle ansehen
Vera Therapeutics Inc Aktie (VERA) Neueste Nachrichten
Vera Therapeutics completes enrollment for IgAN drug trial By Investing.com - Investing.com South Africa
Vera Therapeutics stock hits 52-week low at $21.44 By Investing.com - Investing.com South Africa
Vera Therapeutics stock hits 52-week low at $21.44 - Investing.com India
Vera Therapeutics completes enrollment for IgAN drug trial - Investing.com Australia
Vera Therapeutics completes enrollment in ORIGIN Phase 3 trial for atacicept - TipRanks
Vera Therapeutics Completes Full Enrollment in Pivotal ORIGIN Phase 3 Trial for Atacicept in IgAN - GlobeNewswire
Major Milestone: 431 Patients Enrolled in Vera's Groundbreaking IgAN Treatment Trial - Stock Titan
Is Vera Therapeutics Inc (VERA) a threat to investors? - uspostnews.com
Teacher Retirement System of Texas Acquires 3,942 Shares of Vera Therapeutics, Inc. (NASDAQ:VERA) - Defense World
Vera Therapeutics (NASDAQ:VERA) Reaches New 1-Year LowWhat's Next? - MarketBeat
69,724 Shares in Vera Therapeutics, Inc. (NASDAQ:VERA) Bought by Raymond James Financial Inc. - Defense World
Vera Therapeutics stock hits 52-week low at $25.97 By Investing.com - Investing.com South Africa
Vera Therapeutics stock hits 52-week low at $25.97 - Investing.com India
Vera Therapeutics validates Fair Value bearish call with 42% decline By Investing.com - Investing.com UK
Swiss National Bank Purchases 15,700 Shares of Vera Therapeutics, Inc. (NASDAQ:VERA) - Defense World
AlphaQuest LLC Takes Position in Vera Therapeutics, Inc. (NASDAQ:VERA) - Defense World
Vera Therapeutics, Inc. (NASDAQ:VERA) Shares Bought by Charles Schwab Investment Management Inc. - Defense World
Bank of New York Mellon Corp Acquires 7,895 Shares of Vera Therapeutics, Inc. (NASDAQ:VERA) - Defense World
Is Vera Therapeutics (NASDAQ:VERA) Weighed On By Its Debt Load? - simplywall.st
Victory Capital Management Inc. Increases Stake in Vera Therapeutics, Inc. (NASDAQ:VERA) - Defense World
Vera Therapeutics, Inc. (NASDAQ:VERA) Given Average Recommendation of “Buy” by Analysts - Defense World
Vera Therapeutics, Inc. (NASDAQ:VERA) Receives Consensus Recommendation of “Buy” from Analysts - The AM Reporter
Vera Therapeutics (VERA) Expected to Announce Quarterly Earnings on Wednesday - Defense World
Vera Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - The Manila Times
Vera Therapeutics Growth Accelerates: 9 Strategic Hires Secure Equity Package Worth $2.3M - StockTitan
Vera Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(C)(4) - MENAFN.COM
What is HC Wainwright’s Estimate for VERA FY2025 Earnings? - Defense World
Vera Therapeutics: Does The Earlier Otsuka Launch Harm Its Prospects Much? - Seeking Alpha
Cantor Fitzgerald Analysts Lower Earnings Estimates for VERA - Defense World
JPMorgan Chase & Co. Has Lowered Expectations for Vera Therapeutics (NASDAQ:VERA) Stock Price - Defense World
Vera Therapeutics (NASDAQ:VERA) Price Target Cut to $71.00 by Analysts at JPMorgan Chase & Co. - Armenian Reporter
Vera Therapeutics Getting Closer To Key Technical Benchmark - MSN
Rhumbline Advisers Has $2.48 Million Position in Vera Therapeutics, Inc. (NASDAQ:VERA) - Defense World
Q1 EPS Estimates for Vera Therapeutics Boosted by Wedbush - Defense World
(VERA) On The My Stocks Page - news.stocktradersdaily.com
What is Wedbush’s Forecast for VERA FY2029 Earnings? - Defense World
Guggenheim Raises Vera Therapeutics (NASDAQ:VERA) Price Target to $61.00 - Defense World
Vera Therapeutics to Participate in the TD Cowen 45th Annual Health Care Conference - GlobeNewswire
Wedbush Adjusts Price Target on Vera Therapeutics to $34 From $38, Maintains Neutral Rating - Marketscreener.com
Guggenheim raises Vera Therapeutics stock target to $61 - Investing.com India
Can Vera Therapeutics Reveal New Immunology Pipeline Updates at Upcoming TD Cowen Conference? - StockTitan
Optimistic Buy Rating for Vera Therapeutics: Strong Financials and Promising Pipeline Drive Positive Outlook - TipRanks
Vera Therapeutics targets Q2 for IgAN drug results, FDA filing By Investing.com - Investing.com South Africa
Vera Therapeutics 2024 Loss Widens -February 26, 2025 at 08:53 am EST - Marketscreener.com
Vera Therapeutics targets Q2 for IgAN drug results, FDA filing - Investing.com India
Vera Therapeutics Provides Business Update and Reports Fourth Quarter and Full Year 2024 Financial Results - The Manila Times
Earnings Flash (VERA) Vera Therapeutics Posts Full Year 2024 Total Operating Expenses $167.2M - Marketscreener.com
Earnings Flash (VERA) Vera Therapeutics Posts Full Year 2024 Net Loss $-2.75 a Share, vs. FactSet Est of $-2.90 Loss - Marketscreener.com
Vera Therapeutics, Inc. Reports 2024 Business Highlights and Financial Results; On Track for Phase 3 ORIGIN Trial Results and FDA Submission for Atacicept in IgA Nephropathy - Nasdaq
Can Vera's Breakthrough IgAN Therapy Disrupt the $5B Kidney Disease Market? Phase 3 Results Coming Q2 2025 - StockTitan
Vera Therapeutics’ Atacicept Positioned for Growth Amid Market Overreaction to Otsuka’s Sibeprenlimab - TipRanks
Finanzdaten der Vera Therapeutics Inc-Aktie (VERA)
Umsatz
Nettogewinn
Free Cashflow
ENV
Vera Therapeutics Inc-Aktie (VERA) Insiderhandel
| Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
|---|---|---|---|---|---|---|---|
| Fordyce Marshall | PRESIDENT AND CEO |
Feb 26 '25 |
Sale |
27.65 |
9,075 |
250,882 |
204,665 |
10.70%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):